Patents by Inventor Masakatsu Nozaki

Masakatsu Nozaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chitin oligomer composition and/or chitosan oligomer composition and processes for preparation thereof
    Publication number: 20070112183
    Abstract: This invention aims to develop a chitin oligomer composition and/or a chitosan oligomer composition wherein the content of an oligomer from a trimer to a decamer is 60% or more, and to develop a process for preparing the above-mentioned oligomer composition. The object of the invention can be achieved by mixing hydrofluoric acid or hydrohalogenated acid other than hydrofluoric acid and hydrofluoric acid with a chitin-based material and/or a chitosan-based material.
    Type: Application
    Filed: May 6, 2004
    Publication date: May 17, 2007
    Applicants: RESEARCH INSTITUTE FOR PRODUCTION DEVELOPMENT, STELLA CHEMIFA CORPORATION
    Inventors: Hisao Kitano, Hiroshi Shimizu, Masakatsu Nozaki, Fumio Tanimoto, Hirohisa Kikuyama, Masahide Waki, Kanenori Ito, Shinji Hashiguchi
  • Use of zinc tranexamate in the treatment of diabetes
    Patent number: 6358999
    Abstract: A new use of a zinc tranexamate compound in the treatment of diabetes is disclosed. Oral administration of the compound adequately slows down absorption of glucose from digestive tracts by inhibiting &agr;-glucosidase in vivo. The zinc tranexamate compound is also effective in the treatment of insulin-resistant type II diabetes.
    Type: Grant
    Filed: March 7, 2001
    Date of Patent: March 19, 2002
    Assignee: Hamari Chemicals, LTD
    Inventors: Hajime Fujimura, Masakatsu Nozaki, Shun-ichi Tanaka, Reiko Natsuki
  • Use of zinc tranexamate in the treatment of diabetes
    Publication number: 20010031785
    Abstract: A new use of a zinc tranexamate compound in the treatment of diabetes is disclosed. Oral administration of the compound adequately slows down absorption of glucose from digestive tracts by inhibiting &agr;-glucosidase in vivo. The zinc tranexamate compound is also effective in the treatment of insulin-resistant type II diabetes.
    Type: Application
    Filed: March 7, 2001
    Publication date: October 18, 2001
    Inventors: Hajime Fujimura, Masakatsu Nozaki, Shun-ichi Tanaka, Reiko Natsuki